TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02651285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G-CSF medium
Description: incubation of IVF embryos with a specific medium containing G-CSF

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: incubation of IVF embryos with a medium without G-CSF
Study: NCT04079283

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical
Description: Clinical: A diagnostic model incorporating clinical variables (Age, Pathological diagnosis, level of serum tumor biomarkers etc.)

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical
Description: Clinical: A diagnostic model incorporating clinical variables (Age, Pathological diagnosis, level of serum tumor biomarkers etc.)

Intervention type: DIAGNOSTIC_TEST
Intervention: Semantic
Description: Semantic: A diagnostic model incorporating semantic radiological features (shape, location, border, density etc.)

Intervention type: DIAGNOSTIC_TEST
Intervention: Semantic
Description: Semantic: A diagnostic model incorporating semantic radiological features (shape, location, border, density etc.)

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiomic
Description: Radiomic: A diagnostic model incorporating quantitative radiomic features (histogram, texture, morphology etc.)

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiomic
Description: Radiomic: A diagnostic model incorporating quantitative radiomic features (histogram, texture, morphology etc.)
Study: NCT03075293

Intervention type: OTHER
Intervention: Determination of pain management
Description: Determine of pain management given to children with appendicitis in ER according to their medical records
Study: NCT01038674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-IL-20
Description: Anti-IL-20 injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
Study: NCT03680313

Intervention type: PROCEDURE
Intervention: Hypertension outpatient treatment
Description: Patients who have been diagnosed with primary hypertension and meet the conditions of the study will receive outpatient treatment
Study: NCT01828203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical spinal cord decompression
Description: Surgical decompression by means at the discretion of the clinical management team will occur within 24 hours of injury in all subjects. Stabilization will occur at that time but may also include further interventions at a later time.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgical spinal cord decompression
Description: Surgical decompression by means at the discretion of the clinical management team will occur within 24 hours of injury in all subjects. Stabilization will occur at that time but may also include further interventions at a later time.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maintenance of minimum mean arterial pressure (MAP)
Description: Standardized hemodynamic management protocol aimed at maintaining MAP ≥ 85 mm Hg for 7 days using volume augmentation with isotonic crystalloid followed by inotropic support if needed will be applied to all subjects.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Maintenance of minimum mean arterial pressure (MAP)
Description: Standardized hemodynamic management protocol aimed at maintaining MAP ≥ 85 mm Hg for 7 days using volume augmentation with isotonic crystalloid followed by inotropic support if needed will be applied to all subjects.
Study: NCT00464763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00807495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib capsules
Study: NCT03306407

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Improved hand hygiene
Description: The intervention group receives pre-travel advice with a special focus on improved hand hygiene including the use of hand gel sanitizer (Hartmann Sterillium) (bundle intervention)
Study: NCT00600743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSKI181771X (CCK-1R agonist)
Description: Drug one trial vs placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSKI181771X (CCK-1R agonist)
Description: Drug one trial vs placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSKI181771X (CCK-1R agonist)
Description: Drug one trial vs placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSKI181771X (CCK-1R agonist)
Description: Drug one trial vs placebo

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Instructions to binge eat
Description: Subjects will be instructed to binge eat and will also be given either drug or placebo

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Instructions to binge eat
Description: Subjects will be instructed to binge eat and will also be given either drug or placebo

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Instructions to eat normally
Description: Subjects will be instructed to eat normally and will also be given either drug or placebo

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Instructions to eat normally
Description: Subjects will be instructed to eat normally and will also be given either drug or placebo

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Instructions to eat normally
Description: Subjects will be instructed to eat normally and will also be given either drug or placebo

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Instructions to eat normally
Description: Subjects will be instructed to eat normally and will also be given either drug or placebo
Study: NCT04069936

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MILs™ - NSCLC
Description: To evaluate the safety of MILs™ - NSCLC alone in subjects with locally advanced and unresectable or metastatic NSCLC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab in subjects with locally advanced and unresectable or metastatic NSCLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil
Description: To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab with or without tadalafil in subjects with locally advanced and unresectable or metastatic NSCLC
Study: NCT03961204

Intervention type: OTHER
Group type: OTHER
Intervention: Data Collection
Description: No study treatment was administered as part of this study
Study: NCT01193387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
Study: NCT01411462

Intervention type: DEVICE
Intervention: VIBE + drug-eluting balloon
Description: VIBE before and after durg-eluting balloon angioplasty
Study: NCT02736019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Women will receive oral Celecoxib 200mg 2 hours before the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Women will receive oral Tramadol 100 mg 2 hours before the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 1
Description: Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1
Description: Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2
Description: Women will receive an oral placebo similar to celecoxib 2 hours before the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 2
Description: Women will receive an oral placebo similar to celecoxib 2 hours before the procedure
Study: NCT04481451

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae block with ropivacaine 0.2%
Description: Single-shot ultrasound-guided nerve block performed ipsilateral to surgical site.
Study: NCT04663035

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Description: After local anesthesia and intravenous sedative injection, the unipolar needle would be gradually inserted into the lesion and placed on the deepest edge of the lesion. The ablation electrode is a unipolar needle with a bare end of 2 or 3 cm (adjusted to tumor size). The ablation power is 150 watts (range from 100 to 200 watts). In general, the average ablation time for each lesion is about 12 minutes (ranging from 10 to 15 minutes).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: After local anesthesia and intravenous sedative injection, the unipolar needle would be gradually inserted into the lesion and placed on the deepest edge of the lesion. The ablation electrode is a unipolar needle with a bare end of 2 or 3 cm (adjusted to tumor size). The ablation power is 150 watts (range from 100 to 200 watts). In general, the average ablation time for each lesion is about 12 minutes (ranging from 10 to 15 minutes).
Study: NCT01770353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Ferumoxytol 5 mg/kg IV as a single bolus injection, given once.
Study: NCT04481451

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block with ropivacaine 0.2%
Description: Single-shot ultrasound-guided nerve block performed ipsilateral to surgical site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: ropivacaine 0.2% nerve block injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: ropivacaine 0.2% nerve block injection
Study: NCT02068651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance care planning programme
Description: It is a multi-faceted programme which includes an educational component with support of multimedia materials, reflection on personal values and a facilitated discussion between patient and family carer over future care. It will be delivered to each pair of participant and family carer on individual basis. By the end of the programme, each participant will have a personal workbook summarising the advance care planning process for record.
Study: NCT03324139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Description: Patients included in this study group will receive 3,500 IU / 0.2 ml / day of Bemiparina sc, from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients included in this study group will placebo (same presentation as the active drug), from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
Study: NCT03997799

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uniportal lobectomy with complete lymphadenectomy
Description: uniportal lobectomy with complete lymphadenectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uniportal lobectomy with complete lymphadenectomy
Description: uniportal lobectomy with complete lymphadenectomy
Study: NCT02105220

Intervention type: OTHER
Intervention: Respiratory mechanics assessment
Description: Data collection on respiratory mechanics, end expiratory lung volumes, gas exchanges, work of breathing. Data will be obtained by setting different end expiratory pressures and recording esophageal and airways pressure tracings.

Intervention type: OTHER
Intervention: Respiratory mechanics assessment
Description: Data collection on respiratory mechanics, end expiratory lung volumes, gas exchanges, work of breathing. Data will be obtained by setting different end expiratory pressures and recording esophageal and airways pressure tracings.
Study: NCT00045786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-1088
Description: 400 mg/day (200 mg orally twice a day) 800 mg/day (400 mg orally twice a day) 1200 mg/day (600 mg orally twice a day) 1500 mg/day (500 mg orally three times daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-1088
Description: 400 mg/day (200 mg orally twice a day) 800 mg/day (400 mg orally twice a day) 1200 mg/day (600 mg orally twice a day) 1500 mg/day (500 mg orally three times daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-1088
Description: 400 mg/day (200 mg orally twice a day) 800 mg/day (400 mg orally twice a day) 1200 mg/day (600 mg orally twice a day) 1500 mg/day (500 mg orally three times daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-1088
Description: 400 mg/day (200 mg orally twice a day) 800 mg/day (400 mg orally twice a day) 1200 mg/day (600 mg orally twice a day) 1500 mg/day (500 mg orally three times daily)
Study: NCT01401062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fresolimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fresolimumab

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Study: NCT01229150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD6244
Description: For KRAS mutant patients randomized to the single agent arm, AZD6244 75 mg bid (twice a day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: For Wild-Type KRAS patients randomized to the single agent arm, Erlotinib 150 mg qd (every day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD6244 + Erlotinib
Description: For KRAS mutant patients and Wild-Type KRAS patients randomized to the combination arm (arms are stratified based on KRAS mutational status), AZD6244 150 mg qd (every day) + erl (erlotinib) mg qd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD6244 + Erlotinib
Description: For KRAS mutant patients and Wild-Type KRAS patients randomized to the combination arm (arms are stratified based on KRAS mutational status), AZD6244 150 mg qd (every day) + erl (erlotinib) mg qd.
Study: NCT01513239

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6072
Description: Single IV infusion of MK-6072 (10 mg/kg of monoclonal antibody to C. difficile Toxin B)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-3415A
Description: Single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to C. difficile Toxin A and 10 mg/kg of monoclonal antibody to C. difficile Toxin B)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV infusion of normal saline (0.9% sodium chloride)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: SOC for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: SOC for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOC
Description: SOC for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
Study: NCT04435574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: Bovine Lactoferrin 100mg sachets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: 6mg/kg of ferrous sulfate.
Study: NCT00600743

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Instructions to eat normally
Description: Subjects will be instructed to eat normally and will also be given either drug or placebo

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Instructions to eat normally
Description: Subjects will be instructed to eat normally and will also be given either drug or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug one trial vs placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug one trial vs placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug one trial vs placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug one trial vs placebo
Study: NCT03537261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-based Crisis Prevention Institute (CPI) physical management training program (P-CPI)
Description: Parents of children with ASD will be randomly assigned to the 6-hour P-CPI group training session, which includes nonverbal, paraverbal, verbal, and physical intervention techniques. Baseline measures will be administered on the day of training and follow-up measures at 2-week, 1-month, 2-month, and 3-month post baseline. The treatment group will also participate in an in-person follow-up group qualitative interview.
Study: NCT03772743

Intervention type: OTHER
Group type: OTHER
Intervention: Culprit-only revascularization
Description: Implantation of drug eluting stents with biodegradable polymer with struts ≤65 μ in the culprit lesion of the MI. Each patient should receive revascularization with Supraflex stent or its newer versions
Study: NCT03907566

Intervention type: OTHER
Intervention: The Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals
Description: Swallowing function will be evaluated by the Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals
Study: NCT01770353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Ferumoxytol 5 mg/kg IV as a single bolus injection, given once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-398
Description: MM-398 IV over 90 min every 2 weeks, until progressive disease or intolerable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-398
Description: MM-398 IV over 90 min every 2 weeks, until progressive disease or intolerable toxicity
Study: NCT06688838

Intervention type: DRUG
Intervention: Tofacitinib
Description: If a patient does not respond well to DMARDs treatment, then Tofacitinib or TNFi treatment may be used instead.
Study: NCT00573131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OncoGel (Paclitaxel gel)
Description: 6.3 mg/mL tumor volume, injected into the esophagus during endoscopy, once, before starting chemoradiotherapy
Study: NCT06685926

Intervention type: PROCEDURE
Intervention: Supermicrosurgical LVA, Groin Approach Only (lymphatic vessel to recipient vien lumen-to-lumen anastomosis)

Intervention type: PROCEDURE
Intervention: Supermicrosurgical LVA, Conventional Multiple Access Approach Only (lymphatic vessel to recipient vien lumen-to-lumen anastomosis)
Study: NCT06694870

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcutaneous CO2 monitoring
Description: Transuctaneous CO2 monitoring

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcutaneous CO2 monitoring
Description: Transuctaneous CO2 monitoring
Study: NCT03772743

Intervention type: OTHER
Group type: OTHER
Intervention: Complete functionally-guided revascularization
Description: Implantation of drug eluting stents with biodegradable polymer with struts ≤65 μ in the culprit lesion of the MI and in all non culprit lesions with positive functional assessment. Each patient should receive revascularization with Supraflex stent or its newer versions
Study: NCT04551703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenaline saline irrigation
Description: The surgical field is flushed with 20 cc of Adrenaline saline irrigation. This is in contrast to the standard of care, normal saline irrigation.
Study: NCT03851874

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Bariatric surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Bariatric surgery
Study: NCT02339389

Intervention type: OTHER
Intervention: Labor analgesia
Description: Measuring maternal ventilation after placement of epidural analgesia compared to baseline
Study: NCT02787720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family centered empowerment model
Description: The intervention was conducting Family-Centered Empowerment Model. The intervention package had three steps including pre intervention, during intervention and post intervention. The model has four stages including Perceived threat, Problem solving, Educational partnership, and Evaluation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous care model
Description: The intervention was conducting Family-Centered Empowerment Model. The intervention package had three steps including pre intervention, during intervention and post intervention. The model has four stages including Orientation, Sensitization, Control, and Evaluation
Study: NCT02158624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Lucentis 0.5mg
Study: NCT00588003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: anastrozole 1mg/day 11 days before their surgery and to take the last dose of the oral endocrine agent (anastrozole) on the day before their surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No medication before surgery
Study: NCT00109928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone